Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | FYN | P06241 | 3/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 2/20 | 0.36 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6821913 | 0.91 | ADORA1 (0.43) | ADORA1KDM4EALDH1A1GAAHPGD | |
| SCHEMBL6821972 | 0.91 | CAMK2D (0.44) | ADORA1FYNACSS2HPGD | |
| SCHEMBL6822459 | 0.91 | ADORA1 (0.41) | ADORA1L3MBTL1TP53GCGRKDM4E | |
| SCHEMBL6821521 | 0.89 | MAPK1 (0.41) | ADORA1BRD4TP53ALDH1A1HPGD | |
| SCHEMBL6822550 | 0.89 | ADORA1 (0.40) | ADORA1L3MBTL1ACSS2TP53GCGR | |
| SCHEMBL6822338 | 0.88 | MEN1 (0.49) | ADORA1GAA | |
| SCHEMBL6822494 | 0.88 | ADORA1 (0.43) | ADORA1ACSS2TP53ALDH1A1 | |
| SCHEMBL6822105 | 0.87 | ADORA1 (0.43) | ADORA1ACSS2TP53KDM4EALDH1A1 | |
| SCHEMBL6818544 | 0.86 | ADORA1 (0.46) | ADORA1TP53HPGD | |
| SCHEMBL6824733 | 0.86 | ADORA1 (0.43) | ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110763-A1 | Pyrazolopyridine compound and pharmaceutical use thereof | ADRB1, ADRA1D, ADRB3 | ADORA1 22/4885FYN 20/4885NPSR1 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.